April 30, 2018 / 10:48 AM / 3 months ago

BRIEF-Prometic Reports Positive Clinical Data From Its Intravenous Immunoglobulin Pivotal Phase 3 Trial

April 30 (Reuters) - Prometic Life Sciences Inc:

* PROMETIC REPORTS POSITIVE CLINICAL DATA FROM ITS INTRAVENOUS IMMUNOGLOBULIN (IVIG) PIVOTAL PHASE 3 TRIAL

* PROMETIC LIFE SCIENCES INC - PIVOTAL CLINICAL TRIAL MEETS PRIMARY AND SECONDARY ENDPOINTS

* PROMETIC LIFE SCIENCES INC - CLINICAL DATA DEMONSTRATES COMPARABLE EFFICACY TO COMMERCIALLY-APPROVED DRUG

* PROMETIC LIFE SCIENCES INC - PROMETIC IVIG'S SAFETY AND TOLERABILITY PROFILES MAINTAINED WITHOUT ANY SIGNIFICANT DRUG RELATED ISSUES

* PROMETIC LIFE SCIENCES INC - PROMETIC IVIG'S SAFETY AND TOLERABILITY PROFILES MAINTAINED WITHOUT ANY SIGNIFICANT DRUG RELATED ISSUES

* PROMETIC LIFE SCIENCES INC - OVERALL PROMETIC IGIV 10% APPEARED TO BE WELL TOLERATED AND WAS NOT ASSOCIATED WITH ANY SBIS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below